|
|
| Morningstar Overall Rating: |
 |
| Total Assets: |
740.00K |
| Category: |
Health |
| Total Expense Ratio: |
5.13% |
|
| PERFORMANCE & RISK | 31-Jan-10
| YTD Return: |
-0.15% |
| 5y Avg Return: |
4.93% |
| Rank in Category (ytd): |
58 |
| % Rank in Category (ytd): |
34.94% |
| Beta (3y): |
0.35 |
| Morningstar Risk Rating: |
Low |
|
| The investment seeks long-term growth of capital. The fund usually invests at least 95% of assets in common stocks of companies listed on the AMIDEX-TM- Cancer Innovations & Healthcare index. The index tracks the performance of publicly traded biotechnology, pharmaceutical and medical equipment companies that emphasize products and services focused on cancer detection and treatment. It employs a passive management approach to invest assets. The fund may also invest in foreign securities that are traded on a U.S. exchange or in a form of American Depository Receipts. The fund is nondiversified. |
|
| Fund Profile |
|
Help
0.04 (0.60%) 
Summary
Add CNCRX to Portfolio 
Download Data
